Pharm Exec profiles its 2022 Emerging Pharma Leaders.
Click on the links below to read the profiles of Pharm Exec's 2022 Emerging Pharma Leaders.
Naveen Bazaj, Head of Corporate Development, Alector
Gardner Gendron, Chief/US Head of Commercial, NS Pharma
Aida Habtezion, MD, Senior VP, Chief Medical Officer, and Head of Worldwide Medical and Safety, Pfizer
Matthew J. Hawryluk, PhD, Executive VP, Chief Business Officer and Cambridge Site Head, Gritstone bio
Charmaine Lykins, Chief Commercial Officer, Karuna Therapeutics
Divya Chadha Manek, Senior Vice President of Clinical Development, Eyebiotech Limited (EyeBio)
Susan Pandya, MD, Vice President, Clinical Development, and Head of Cancer Metabolism Global Development Oncology and Immuno-Oncology, Servier Pharmaceuticals
Matthew R. Price, Co-Founder, Executive Vice President, Chief Operating Officer, and Board Director, Promontory Therapeutics
Quiona Russell, PhD, Associate Director of Medical Information and Medical Communication, G1 Therapeutics
Patricia Torr, US President and General Manager, Idorsia Pharmaceuticals
Shetal Vyas, Vice President of Operations, Ferring Pharmaceuticals
*From a pool of nominations, these final selections were judged in a blinded process by three Pharmaceutical Executive Editorial Advisory Board members and a former EPL. Selections were based on a number of criteria and review of professional accomplishments and progression of responsibilities in line with executives most likely to inhabit key “c-suite” functions.
The State of Mining Data Insights in the Life Sciences Industry – 2024
April 30th 2024A Frost & Sullivan industry-wide survey reveals which insights most pharmaceutical companies have mastered and which are still painful or impossible to extract and details the complexity of the process, the confidence companies have in their findings, and more. Hear Web Sun, President and Co-founder of Komodo Health, share what's driving these challenges and how you can overcome them.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.